

As of 6/15/2020

Listed:	OTC
Symbol:	RTSL
Market Cap:	\$40,782,560
Shares Outstanding:	156,856,000
Public float:	16,856,000
Recent Price:	\$0.21
Fully Reporting OTC Pink Sheets; OTCQB uplist pending; Eligible for DWAC	



5580 Peterson Lane, Suite 200 Dallas, TX 75240

Phone: 800-497-6059 Fax: 877-676-8527

Email: info@rtslco.com

Corporate Website: www.rtslco.com

Branded Website: www.rxoid.com

Contact: investor@rtslco.com

Corporate Overview

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), an early stage, emerging biotech company focused on aerosol delivery of medication in the legal hemp and cannabis space, has acquired the rights to certain IP owned by Texas MDI, Inc. (TMDI). TMDI's wholly owned subsidiary Rxoid™ Health Solutions, LLC, (Rxoid™) is a licensee of EM3 Methodologies, LLC (EM3). Under its license with EM3, Rxoid™ has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a meter dose inhaler (MDI). Rxoid™ manufactures all MDI in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient method of delivery of an API other than an IV. RTSL's MDI are a safe replacement for vape pens and delivers a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. The current vape market in the US is estimated to be \$5 Billion. An MDI is the replacement for vape pens as it uses no heat and needs no dangerous ingredients to work. In addition, MDI are less expensive than any other route of delivery measured by blood serum levels. They are however very expensive to formulate so that they legally and properly work as an MDI under FTC rules on truth and labeling.

Rxoid™ CBD inhalers are currently being sold through doctors' offices and in pharmacies across the United States. RTSL is certified by CMDICB (<http://cmdicb.com/>) for product safety. RTSL's MDI are covered by products liability insurance. The estimated net margin on sales of 10,000 MDI/ month at wholesale is approximately \$100,000 to \$250,000 depending on volume. The company is presently selling about 10,000 units per month via wholesale.

This summer, RTSL will begin marketing **inhāler**, a new consumer-focused brand of health and wellness lines that achieve the so-called "entourage" effect using proprietary terpene blends approved for inhalation. In addition to its CBD formulations, RTSL has successfully formulated CBN and CBD/CBN blends and 16 health and wellness lines.

An intense focused digital internet and channel focused geo-marketing campaign is scheduled to launch during late June to early July 2020. RTSL has retained the marketing group which rolled out the highly successful JUUL Device. This group is 45 days into developing RTSL's digital campaign including ad release strategies and branded websites. RTSL has full-time experienced sales and marketing personnel addressing strategic markets for Rxoid™ as well as **inhāler**.

Negotiations for large (>100,000/mo.) white labeling opportunities are ongoing in the US, Brazil, Mexico, Israel, Ecuador, Greece, and the European Union. RTSL is also in final stage negotiations to produce MDI containing THC in CA and OK. RTSL's Rxoid™ product line is in the preliminary stage of human pharmacokinetic (PK) studies on pain and osteoarthritis patients using CBD.

Sublicensed IP:

- RTSL acquired its sublicense from TMDI in exchange for 140,000,000 common shares and installation of Donal R. Schmidt, Jr. as CEO/COB. The sublicense agreement with EM3 grants RTSL exclusive territories for the states of CA, TX, FL and NV for its MDI for both hemp and cannabis formulations and equipment sales and unrestricted access to the rest of the world.

Development of Other Cannabinoid Product Lines

- RTSL is currently testing formulations of CBN, THCva, tadalafil (Cialis) and a natural formulated replacement for amphetamines used to treat ADHD such as Adderall.

White Label Negotiations

- RTSL is white labeling MDI in multiple jurisdictions. The first major contract is two months into production. Manufacturing under this contract of 100,000 units began in March 2020. White label discussions also focus on wholesale distributors and major chain retailers. In addition, the company is working with members of several professional sporting groups to bring its product to professional sports leagues, their current players, and their retired alumni.

FDA Registration

- RTSL has begun the process to obtain FDA approval of its entire product line. RTSL is registered with the FDA and expects to be able to label their products as such in 3-4 weeks once the Covid-19 virus allows the FDA to resume full staffing. Full approval is expected within 1-2 years under deemed rules being developed by the FDA for CBD similar to those for tobacco.

Management

Industry Experienced Management Team: CEO and Sr. VP have several years working together as independent consultants to the hemp and cannabis markets. Together they have invested ~ \$1.25 Million in Rxoid™.

- Donal R. Schmidt, Jr. (59) – CEO/COB – Prior to Rxoid™, president of several public companies; Licensed attorney, CPA, and MBA in Finance University of Texas, Degrees in Math and Chemistry.
- Sean Berrier (48) – Senior VP – 30 years of diversified experience in the hemp and cannabis space in all areas of the industry. Owned and operated hemp and cannabis farms in Oregon for 5 years.
- Hughes Watler (70) – CFO/Board Member – CPA with 25 plus years of senior management in public companies including CFO of NSYE company with \$1Billion market cap; MBA University of Texas.
- Ryan Southern (40) – VP of Marketing and Client Relations - Pharmaceutical marketing experience of 18 years with major prescription and GRAES product lines such as Mucinex.
- Robert (Rob) Renick (59) – VP of Sales - 25 plus years of senior management experience with large MLM and Affiliate marketing groups in both national and international territories.
- Richard (Rick) Adams, Ph.D. (50) – Chief Technical Science officer - Stanford trained anesthesiologist with Ph.D. in Organic Chemistry.

Nine Reasons to Invest in Rapid Therapeutic Science Laboratories (RTSL) today...!

- Industry leader in MDI formulation and manufacturing in CBD and legal Cannabis space.
- Super pure formulation process with 98% bioavailability to replace vape pens, edibles and tinctures.
- Annual run-rate approaching \$2.5M and should ramp up rapidly with introduction of **inhāler** product line.
- **Rxoid™** product line has been on market since early 2020 and is enjoying wide-spread acceptance
- Product being successfully tested by NFL, MLB and collegiate athletes.
- Clean balance sheet – zero long term debt after completion of next \$250,000 in funding.
- Management has 150+ years of successful private/public company, domain and capital markets experience
- Tightly controlled cap structure; TMDI holds over 85% of outstanding shares.

Anticipated Exit Opportunity for Individual Shareholders (Ninth Reason)

- RTSL expects a NASDAQ uplisting within the next fiscal year and/or an acquisition by a major health company within 24 months which could provide significant upside for selling shareholders; private placement shares acquired would be freely tradable in six months under Rule 144.

This overview contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this overview which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this overview, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.